Research ExplorerPublicationsImpact of primary disease on outcome after allogeneic stem c...

Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia

Standard

Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia. / Kröger, Nicolaus; Eikema, Diderik-Jan; Köster, Linda; Beelen, Dietrich; de Wreede, Liesbeth C; Finke, Jürgen; Koenecke, Christian; Niederwieser, Dietger; Bornhäuser, Martin; Schoenland, Stefan; Potter, Victoria; Wolschke, Christine; Maertens, Johan; Theobald, Matthias; Kobbe, Guido; Itälä-Remes, Maija; Wulf, Gerald; Kahls, Peter; Forcade, Edouard; Greinix, Hildegard; Masszi, Tamás; Yakoub-Agha, Ibrahim; Chalandon, Yves; Robin, Marie; Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

In: BRIT J HAEMATOL, Vol. 185, No. 4, 05.2019, p. 725-732.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Kröger, N, Eikema, D-J, Köster, L, Beelen, D, de Wreede, LC, Finke, J, Koenecke, C, Niederwieser, D, Bornhäuser, M, Schoenland, S, Potter, V, Wolschke, C, Maertens, J, Theobald, M, Kobbe, G, Itälä-Remes, M, Wulf, G, Kahls, P, Forcade, E, Greinix, H, Masszi, T, Yakoub-Agha, I, Chalandon, Y, Robin, M & Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT) 2019, 'Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia', BRIT J HAEMATOL, vol. 185, no. 4, pp. 725-732. https://doi.org/10.1111/bjh.15819

APA

Kröger, N., Eikema, D-J., Köster, L., Beelen, D., de Wreede, L. C., Finke, J., Koenecke, C., Niederwieser, D., Bornhäuser, M., Schoenland, S., Potter, V., Wolschke, C., Maertens, J., Theobald, M., Kobbe, G., Itälä-Remes, M., Wulf, G., Kahls, P., Forcade, E., ... Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (2019). Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia. BRIT J HAEMATOL, 185(4), 725-732. https://doi.org/10.1111/bjh.15819

Vancouver

Kröger N, Eikema D-J, Köster L, Beelen D, de Wreede LC, Finke J et al. Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia. BRIT J HAEMATOL. 2019 May;185(4):725-732. https://doi.org/10.1111/bjh.15819

Bibtex

@article{0db67ebc4e294be8a4df19927967917e,
title = "Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia",
abstract = "Myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN) and chronic myelomonocytic leukaemia (CMML) can progress to secondary acute myeloid leukaemia (sAML). We compared the outcome of 4214 sAML patients who received allogeneic haematopoietic stem cell transplantation (allo-HSCT) from an unrelated (62%) or human leucocyte antigen (HLA)-identical sibling donor (38%) according the underlying disease: MDS (n = 3541), CMML (n = 251) or MPN (n = 422). After a median follow up of 46·5 months, the estimated 3-year progression-free (PFS) and overall survival (OS) for the entire group was 36% (34-37%) and 41% (40-43%), respectively. The cumulative incidence of relapse and non-relapse mortality (NRM) was 37% (35-39%) and 27% (26-29%), respectively. In a multivariable analysis for OS, besides age (P < 0·001), unrelated donor (P = 0·011), cytomegalovirus ± constellation (P = 0·007), Karnofsky index ≤ 80 (P < 0·001), remission status (P < 0·001), peripheral blood as stem cell source (P = 0·009), sAML from MPN (P = 0·003) remained a significant factor in comparison to sAML from MDS, while worse outcome of sAML from CMML did not reach statistical significance (P = 0·06). This large registry study demonstrates a major impact of the underlying disease on outcome of sAML after allo-HSCT.",
author = "Nicolaus Kr{\"o}ger and Diderik-Jan Eikema and Linda K{\"o}ster and Dietrich Beelen and {de Wreede}, {Liesbeth C} and J{\"u}rgen Finke and Christian Koenecke and Dietger Niederwieser and Martin Bornh{\"a}user and Stefan Schoenland and Victoria Potter and Christine Wolschke and Johan Maertens and Matthias Theobald and Guido Kobbe and Maija It{\"a}l{\"a}-Remes and Gerald Wulf and Peter Kahls and Edouard Forcade and Hildegard Greinix and Tam{\'a}s Masszi and Ibrahim Yakoub-Agha and Yves Chalandon and Marie Robin and {Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT)}",
note = "{\textcopyright} 2019 British Society for Haematology and John Wiley & Sons Ltd.",
year = "2019",
month = may,
doi = "10.1111/bjh.15819",
language = "English",
volume = "185",
pages = "725--732",
journal = "BRIT J HAEMATOL",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "4",

}

RIS

TY - JOUR

T1 - Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia

AU - Kröger, Nicolaus

AU - Eikema, Diderik-Jan

AU - Köster, Linda

AU - Beelen, Dietrich

AU - de Wreede, Liesbeth C

AU - Finke, Jürgen

AU - Koenecke, Christian

AU - Niederwieser, Dietger

AU - Bornhäuser, Martin

AU - Schoenland, Stefan

AU - Potter, Victoria

AU - Wolschke, Christine

AU - Maertens, Johan

AU - Theobald, Matthias

AU - Kobbe, Guido

AU - Itälä-Remes, Maija

AU - Wulf, Gerald

AU - Kahls, Peter

AU - Forcade, Edouard

AU - Greinix, Hildegard

AU - Masszi, Tamás

AU - Yakoub-Agha, Ibrahim

AU - Chalandon, Yves

AU - Robin, Marie

AU - Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

N1 - © 2019 British Society for Haematology and John Wiley & Sons Ltd.

PY - 2019/5

Y1 - 2019/5

N2 - Myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN) and chronic myelomonocytic leukaemia (CMML) can progress to secondary acute myeloid leukaemia (sAML). We compared the outcome of 4214 sAML patients who received allogeneic haematopoietic stem cell transplantation (allo-HSCT) from an unrelated (62%) or human leucocyte antigen (HLA)-identical sibling donor (38%) according the underlying disease: MDS (n = 3541), CMML (n = 251) or MPN (n = 422). After a median follow up of 46·5 months, the estimated 3-year progression-free (PFS) and overall survival (OS) for the entire group was 36% (34-37%) and 41% (40-43%), respectively. The cumulative incidence of relapse and non-relapse mortality (NRM) was 37% (35-39%) and 27% (26-29%), respectively. In a multivariable analysis for OS, besides age (P < 0·001), unrelated donor (P = 0·011), cytomegalovirus ± constellation (P = 0·007), Karnofsky index ≤ 80 (P < 0·001), remission status (P < 0·001), peripheral blood as stem cell source (P = 0·009), sAML from MPN (P = 0·003) remained a significant factor in comparison to sAML from MDS, while worse outcome of sAML from CMML did not reach statistical significance (P = 0·06). This large registry study demonstrates a major impact of the underlying disease on outcome of sAML after allo-HSCT.

AB - Myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN) and chronic myelomonocytic leukaemia (CMML) can progress to secondary acute myeloid leukaemia (sAML). We compared the outcome of 4214 sAML patients who received allogeneic haematopoietic stem cell transplantation (allo-HSCT) from an unrelated (62%) or human leucocyte antigen (HLA)-identical sibling donor (38%) according the underlying disease: MDS (n = 3541), CMML (n = 251) or MPN (n = 422). After a median follow up of 46·5 months, the estimated 3-year progression-free (PFS) and overall survival (OS) for the entire group was 36% (34-37%) and 41% (40-43%), respectively. The cumulative incidence of relapse and non-relapse mortality (NRM) was 37% (35-39%) and 27% (26-29%), respectively. In a multivariable analysis for OS, besides age (P < 0·001), unrelated donor (P = 0·011), cytomegalovirus ± constellation (P = 0·007), Karnofsky index ≤ 80 (P < 0·001), remission status (P < 0·001), peripheral blood as stem cell source (P = 0·009), sAML from MPN (P = 0·003) remained a significant factor in comparison to sAML from MDS, while worse outcome of sAML from CMML did not reach statistical significance (P = 0·06). This large registry study demonstrates a major impact of the underlying disease on outcome of sAML after allo-HSCT.

U2 - 10.1111/bjh.15819

DO - 10.1111/bjh.15819

M3 - SCORING: Journal article

C2 - 30820933

VL - 185

SP - 725

EP - 732

JO - BRIT J HAEMATOL

JF - BRIT J HAEMATOL

SN - 0007-1048

IS - 4

ER -